Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
Categories: NABNews

Omdia projects 124% growth in generative AI software market for 2024 as enterprises explore potential

LONDON, June 17, 2024 /PRNewswire/ — Generative AI (GenAI) software revenue will increase at a 53% CAGR from 2023 to reach $58 billion by 2028, Omdia’s latest Artificial Intelligence Software Market Forecasts reveals. GenAI software revenue will grow by 124% in 2024, revised upward from the prior forecast of 100%.

Many vendors with large language models (LLMs) are seeing revenue run rates that suggest triple-digit revenue growth in 2024. Top SaaS vendors have been continually adding new GenAI features to existing products, sometimes monetizing that with premium-tier subscription offerings. Some GenAI tools, like the GitHub CoPilot, are experiencing a surge in adoption.

Enterprises have also been eager to allocate GenAI budgets in 2024 (and expect to increase those budgets in 2025) to see what the technology offers and to stay ahead of competitors, as shown in Omdia’s Generative AI Enterprise Survey: Early Adopters – 2024. Omdia expects market growth to slow over the forecast horizon, primarily due to market maturation but also as actual GenAI results in some cases fail to meet heady expectations and overinvestment. The Omdia survey shows that the majority of enterprises who have deployed GenAI say it is meeting expectations, but that sentiment is not unanimous, and some projects are failing to deliver.

“While we see a near-term frenzy in GenAI interest and actual adoption,” said Neil Dunay, Omdia Principal Forecaster, “the prospects for disillusionment are real.”

Some of the top use cases for GenAI in 2024 will be automated code development, virtual assistants, computer-aided art and photography, video and audio production, and writing assistants.

Growth in GenAI is eclipsing growth in predictive (traditional) AI software revenue, which is entering a more mature phase. Omdia forecasts predictive AI software revenue will reach $136 billion in 2028, a 14% CAGR.

Updated twice a year, Omdia’s Artificial Intelligence Software Market Forecasts covers both generative and predictive AI, forecasting revenue for approximately 160 use cases by 20 industry sectors across 8 world geographic regions. Revenue is estimated only for the AI technology portion (AI value-add), not the entire software solution.

About Omdia

Omdia, part of Informa Tech, is a technology research and advisory group. Our deep knowledge of tech markets combined with our actionable insights empower organizations to make smart growth decisions.

Fasiha Khan Fasiha.khan@omdia.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/omdia-projects-124-growth-in-generative-ai-software-market-for-2024-as-enterprises-explore-potential-302174384.html

SOURCE Omdia

Staff

Recent Posts

TRG Studios Is Becoming Pixel Tiger

Dallas ad agency's in-house production studio rebrands, expanding production opportunitiesDALLAS, March 31, 2026 /PRNewswire/ --…

2 hours ago

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

BEIJING, March 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a…

2 hours ago

DPA Microphones N-Series Deployed for the First Time in Argentina at the Teatro Colón for “Astor Piazzolla, Eterno”

BUENOS AIRES, ARGENTINA, MARCH 31, 2026 ― When the Teatro Colón opens its doors to…

11 hours ago

Creative Technology Group (CT) Adds Analog Way Aquilon RS6 For Live Event Production

Creative Technology Group, Inc. (CT), the NEP Live Events group, has invested in multiple Analog…

13 hours ago

Ai Global Solutions Becomes n8n Expert Partner to Advance AI-Driven Automation

AiGS will leverage n8n's platform to deliver future-ready automation solutions that streamline operations and unlock…

15 hours ago

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety…

15 hours ago